The Board of Directors declared a quarterly cash dividend of $0.08 per share for the quarter ended September 30, 2026. The payment is scheduled for November 23, 2026, to shareholders of record as of November 13, 2026, provided that Bio-Techne's pending acquisition by Merck KGaA, Darmstadt, Germany has not closed by the record date. Future dividends will be evaluated quarterly. Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.
